IHPC Testimony to FDA on Homeopathy Hearings

On Monday April 20, IHPC Executive Director Alyssa Wostrel is providing live testimony to the FDA as part of its two-day hearing as part of its review of regulation framework.

The hearing is entitled:

Homeopathic Product Regulation:
Evaluating the Food and Drug Administration Regulatory Framework
After a Quarter Century.

A live webcast of the hearing is available here.
Ms. Wostrel’s remarks are scheduled for 3:30 PM April 20.

Click here for FDA’s information page about the hearing and the Public Comment Period extending into June.


IHPC Executive Director Alyssa Wostrel

As reported by the Washington Post: “‘The FDA has not made any decisions about whether to change how it approaches homeopathic products,’ said Cynthia Schnedar, director of the Office of Compliance at the FDA’s Center for Drug Evaluation and Research. ‘At this stage,’ she said, ‘we are gathering information about whether to adjust our current enforcement policy.'”

IHPC joins 37 other organizations who will present during the two-days, including IHPC member organizations the American Association of Naturopathic Physicians (ANP), The National Center for Homeopathy (NCH), and Samueli Institute.

The IHPC statement includes citations from the NIH (NCCAM) national consumer survey of 2008 that shows significant adoption of homeopathy, as well as research studies published by medical journals.

A PDF copy of Ms. Wostrel’s remarks is available here..

IHPC will post to Facebook and Twitter during the presentation from our handles @theIHPC and @CoverMyCare.

The Washington Post article can be found here.

  1. Domenick Masiello

    My written comments to the FDA are posted on my website at –


  2. Pingback: FDA Hearings -Speakers | homeopathyhub

Leave a Reply


captcha *